There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available;dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.
There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available;dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.
Arner, Peter; Kulyté, Agné; Batchelor, Kenneth et al. (2018) Mapping of biguanide transporters in human fat cells and their impact on lipolysis. Diabetes Obes Metab 20:2416-2425 |